NCT06493760View on ClinicalTrials.gov

A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients

PHASE2RecruitingINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

September 3, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2027

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

SSGJ-707

bispecific antibody

DRUG

Bevacizumab

VEGF antibody

DRUG

Oxaliplatin

chemotherapy

DRUG

Capecitabine

chemotherapy

DRUG

Calcium Folinate

chemotherapy

DRUG

5-fluorouracil

chemotherapy

Trial Locations (1)

Unknown

RECRUITING

Liu Tianshu, Shanghai

All Listed Sponsors

lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY